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A Comparative Pulse Accuracy Study of 
Two Commercially Available Patch Insulin 
Infusion Pumps
Jenna L Bowen and Chris J Allender
School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, UK
B
ackground: Patch pumps are a relatively new method of insulin delivery. This study explores the accuracy of patch-pumps by 
reporting on comparative pulse-accuracy study of two patch pumps. Methods: The accuracy of two patch pumps (Cellnovo, 
[Cellnovo Ltd., Swansea, UK] and OmniPod® [Ypsomed Ltd, Escrick, UK]) was evaluated micro-gravimetrically. Pulse accuracy was 
analysed by comparing single and time-averaged pulses for each device. Results: Single-pulses outside accuracy thresholds ±5%, ±10%, 
±15%, ±20%, ±25% and ±30% were: Cellnovo; 79.6%, 55.6%, 35.0%, 19.9%, 9.7% and 4.3%; OmniPod; 86.2%, 71.6%, 57.4%, 45.5%, 35.2% 
and 25.4%. For 10, 20 and 40 pulse-windows mean values outside ±15% accuracy level were: Cellnovo; 7.3%, 1.5% and 0.4%, OmniPod; 
37.6%, 31.8% and 25.9. Conclusions: This study showed that not all patch pumps are the same. The pumping mechanisms employed in 
these pumps play a significant role in the accuracy and precision of such devices.
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Insulin pumps provide a convenient way of delivering a continuous subcutaneous insulin 
infusion (CSII). Devices are highly flexible to individual patient needs, allowing personalised 
24-hour basal infusions and on-demand bolus delivery for acute periods of elevated 
blood glucose (for example, carbohydrate consumption during meals). Insulin pumps offer 
patients certain advantages over multiple daily injection (MDI) regimens including fewer 
injections, more flexibility and the ability to better fine-tune regimens to their personal 
lifestyle/needs.1 Clinically, they have been shown in randomised, controlled trials to provide 
improved glycaemic control (lower glycated haemoglobin [HbA1c])
2,3 reduce the frequency of 
hypoglycaemic episodes,3,4 and enhance quality of life versus specific MDI regimens in type 
1 diabetes mellitus.2 For the paediatric population, quality of life gains, extend beyond pump 
users to their families and carers.5
Several varieties of insulin pump are commercially available, with the two main products 
being durable pumps and patch pumps. Durable pumps are the most common and include 
an infusion set that connects the subcutaneous cannula to the pump device via an infusion 
line (~30-100 cm). Examples include the Animas Vibe® and the Animas Ping® (Animas, West 
Chester, Pennsylvania, US), the Accu-Chek® Combo (Roche, Basel, Switzerland), the MiniMed 
Paradigm®Veo™ (Medtronic, Dublin, Republic of Ireland) and the DANA Diabecare R® (Advanced 
Therapeutics, Sooil, Seoul, Korea). 
Unlike durable pumps, patch pumps are free of infusion sets as the cannula and delivery system 
are built into the device. They are worn directly on the body and controlled by a wireless device 
making them more discrete than the traditional durable pumps. Patch pumps aim to increase 
patient compliance by providing freedom from long-tubing, increased flexibility, easier technical 
operation and a smaller, lightweight device capable of being manipulated discretely.6 Examples 
include the OmniPod® (Insulet Corporation, Billerica, Massachusetts, US) and the Cellnovo system 
(Cellnovo Ltd., Swansea, UK).
Whilst patch pumps offer clear aesthetic advantages, a recent study found the dosing accuracy 
of the OmniPod patch pump to be unfavourable when compared to several durable pumps.7 Jahn 
et al.7 demonstrated that the patch pump was significantly less accurate in terms of both single-
pulse and averaged-pulse accuracy, than the traditional durable pumps. Unfortunately, only one 
patch pump (OmniPod) was investigated versus three durable pumps (OneTouch Ping, Accu-Chek 
Combo and the MiniMed Paradigm Revel™/ Veo). In another study, Cappuro et al.8 sought to 
compare the dose precision performance of the Animas Vibe and t:slim® (Tandem® Diabetes Care, 
San Diego, California, US) durable pumps and the OmniPod patch pump over three delivery phases 
in a 20 hour test. Results showed that across all delivery stages and in terms of dose variability, the 
OmniPod did not perform as well as the Animas Vibe.
DOI: http://doi.org/10.17925/EE.2016.12.02.79
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A number of methods are available to compare pumps, including those 
referenced in the Worldwide Standard EN 60601-2-24:2012, methods 
using pipettes, microscopes and imaging software13 as well as the 
method described by Jahn et al.7 
To date no groups have sought to compare dosing accuracy between 
commercially available patch pumps. We report a comparative pulse 
accuracy study comparing OmniPod and Cellnovo patch pump devices. 
The Cellnovo system utilises a post-reservoir, wax-powered micro-pump 
and micro-fluidics that dispenses insulin on demand in a pulsatile fashion. 
It has a closed-loop feedback mechanism that continually interrogates a 
reservoir position sensor residing within the durable element of the 
pump. It has the ability to make drop-by-drop alterations to the delivered 
volume to ensure continuous, accurate delivery. By contrast, the 
OmniPod system employs a more traditional disposable syringe pump 
mechanism to actuate movement of its reservoir plunger, relying on a 
shape-memory alloy to drive its motor, utilising a paired tick-tock action. 
The Cellnovo system is approved for use within the EU through its CE 
Mark, the OmniPod system is available for use within the US as well as 
the EU and other countries.
The Methodology employed in this study was a slightly modified version 
of that described by Jahn et al.7 Specific adjustments were made to the 
setup to account for comments made by Zisser12 regarding the potential 
for mechanical oscillations to create measurement spikes when 
housing the patch pumps within the measurement equipment. Pumps 
were compared by evaluating single and average-pulse accuracy over 
clinically relevant periods of pump use. It is important to note that this 
was not intended to be a clinical study, merely one that evaluates relative 
technical performance of two patch pump systems. 
Materials and methods
The accuracy of the OmniPod and Cellnovo patch pump devices was 
investigated using a modified version of the time-stamped micro-
gravimetric system reported by Jahn et al.7 (Figure 1). The system 
comprised two Discovery DV215CD semi-micro analytical balances (81 g 
capacity, 0.00001 g resolution, Ohaus, Nänikon, Switzerland) positioned 
on a robust low-vibration table. Balances were internally calibrated 
before use and all measurements performed at room temperature with 
the balance draft-shield doors closed. Balance data was captured at 
90-second intervals using Quod Pump Controller V6.1 software (Cellnovo 
Ltd., Swansea, UK). The Quod Pump Controller software is designed to 
record balance data at predetermined time intervals. The software was 
set to capture data at a frequency greater than the delivery frequency.
A circular plastic vial (diameter 4 cm, capacity 25 ml) was filled 
with 15 ml deionised water and placed on the weighing pan of the 
balance. A thin layer of paraffin oil (1.5 ml) was applied to the top of 
the water. This volume of oil sufficiently covered the surface of the 
water, minimising evaporation during experimental runs. Patch pump 
devices were positioned outside of the balance and connected to 
the pre-filled plastic vial via clear, flexible infusion lines (60 cm length, 
0.8 mm i.d., 2.4 mm o.d., TYGON R-3603 laboratory tubing [Fisher 
Scientific UK Ltd., Leicestershire, UK]) of similar diameter to the devices’ 
cannula (OmniPod) or connector (Cellnovo). For the OmniPod device, 
the infusion line was sealed around the base of the cannula using 
UV-activated resin (BUG-BOND™). To ensure that the OmniPod was 
connected appropriately and running properly, discrete bolus pulses 
were delivered to prime the infusion line and to ensure, through careful 
observation, that the system was leak and obstruction free. A 60 cm 
length was chosen to ensure that the tubing was of a reasonable kink-
free length from the patch pumps to the weighing system. The Cellnovo 
device came fitted with an outlet valve connector that was used to 
connect the device to the infusion line. Within the balance ‘cabinet’ the 
infusion line was fitted with a needle (length, 3.5 cm) the end of which 
was positioned through the paraffin oil layer to project (~2 mm) into the 
underlying water. The needle was projected into the underlying water 
to reduce any evaporation effects and to ensure that each drop was 
fully assimilated into the underlying water in a way that the increased 
mass could be measured. To reduce the effects of siphoning, the patch 
pump devices were positioned on stages so that the device output 
valve/cannula was level with the tip of the needle in the collecting vial. 
As in Jahn et al.,7 de-gassed deionised water was used as a surrogate 
neutral infusion fluid for fast-acting insulins giving comparable fluid 
properties. This complies with the international standard set out in EN 
60601-2-24:2012 that with regard to the testing of essential performance 
of infusion pumps and controllers, requires the use of a liquid which can 
be expected to give similar test results to the liquid intended for use.9
Both devices were loaded with deionised water primed and programmed 
as specified by the manufacturer’s instructions. As both pumps deliver 
fixed 0.5 µl volumes, the rate of insulin delivery was controlled by 
varying the number of pulses per hour.10 For both pumps and for all 
runs, the initial pulse rate was set to 0 µl/hour for 1 hour in order to 
gauge system stability and measure weight-loss due to evaporation. 
All pumps were then run for 200 pulses per run. Evaporation and 
system stability was again, evaluated at a pulse rate of 0 µl/hour for 
one hour immediately post the 200 pulse run period (Table 1). The total 
run time was therefore 22 hours with weights recorded every 90 
seconds (two measurements for each delivery point) to ensure delivery 
was measured correctly at each point.
A total of 30 runs were completed for each device (n=30, two repetitions 
for each of 15 different pumps). Each pump was limited to two repeats 
due to the 72-hour expiry of the pumps after priming. Comparisons 
between pulse data of the devices were made for the 20-hour test basal 
rate period.
Figure 1: Schematic of the test apparatus used to 
investigate patch pump accuracy
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Data analysis
Data for each individual 0.5 µl pulse were isolated, and recorded. Pulse 
volume was derived directly from pulse weight (DW, simply the weight 
difference recorded by the balance between discrete pulse) using 
equation 1. The percentage error in pulse volume was then calculated 
according to equation 2.
	 DW(µg) 
= pulse delivered (µl) 
Equation 1
998.21 (µg H
2
O ml–1)
 Volume pulse–Volume pulse   Equation 2
 delivered expected  
× 100 = % Error in pulse volume
 Volume pulse expected
Single-pulse accuracy 
For both devices, single-pulse accuracy (percentage deviation from 
expected pulse volume) was analysed for each discrete pulse delivered 
over the 30 runs (n=6000 pulses) according to equation 2. Using these 
data the number of discrete pulses with percentage error greater than 
predetermined accuracy thresholds (±5, 10, 15, 20, 25 and 30% deviation 
from expected pulse volume) was calculated and compared for the two 
patch pump devices.
Averaged pulse accuracy
Although investigating single-pulse accuracy is a valid metric to assess 
pump performance, averaged-pulse accuracy over sustained periods 
of pump delivery may be a more clinically relevant assessment since 
patch pumps are used continuously and the time to reach steady-state 
will vary. Averaged pulse accuracy was analysed by averaging discrete 
pulse errors over predetermined observation windows. For example, at 
a dosing rate of 1 unit per hour, 10, 20 and 40 consecutive pulse errors 
were averaged to calculate the averaged-pulse accuracy over a 0.5 units, 
1 unit and 2 units respectively.
Typical patch pump performance
To further compare the two pumps, and specifically to gain insight into 
the underlying pumping mechanisms, a ‘typical performer’ was selected 
from the 15 individual devices tested for both OmniPod and Cellnovo. The 
typical pump was selected as the pump that had the median standard 
deviation in discrete pulse error over the 20-hour test basal rate period.7 
Statistical analysis
Unpaired t-tests were used for all comparisons between the devices. 
The standard deviation of discrete dose percentage errors was calculated 
for each of the 30 experimental runs for both devices.
Results
Single-pulse accuracy
Investigating the accuracy of discrete pulses is one way of assessing the 
performance of insulin infusion pumps. Figure 2 shows the percentage 
error in single-pulse volume for each pulse delivered over the 30 
experimental runs for the Cellnovo (Figure 2A) and OmniPod (Figure 2B) 
devices. Single-pulse accuracy ranged from -120.0% to 158.5% for the 
OmniPod pump and -51.6% to 61.8% for the Cellnovo pump.
The percentage of single pulses delivered outside accuracy thresholds of 
±5%, ±10%, ±15%, ±20%, ±25% and ±30% were: Cellnovo 79.6%, 55.6%, 
35.0%, 19.9%, 9.7% and 4.3%; OmniPod 86.2%, 71.6%, 57.4%, 46.5%, 35.2% 
and 25.4%) (Figure 3, Table 2). There is a significant difference between 
Cellnovo and OmniPod value for all of these thresholds (p<0.0001).
Averaged pulse accuracy
An alternative and perhaps more clinically relevant way to assess patch 
pump performance is to investigate averaged pulse accuracy over 
extended periods of delivery. The averaged pulse accuracy of the pumps 
was investigated over pre-determined observation windows of 10, 20 
and 40 pulses (nominally 0.5, 1.0 and 2.0 units) (Figure 4, Table 2). For 
both pumps the averaged-pulse accuracy improved as the observation 
window increased. The percentage of pulses delivered outside 
of the ±15% accuracy threshold over 0.5 unit, 1.0 unit, and 2.0 unit 
observation windows, were: Cellnovo 7.3%, 1.5% and 0.4%; OmniPod 
37.6%, 31.8% and 25.9% respectively (Figure 4). There is a significant 
difference between Cellnovo and OmniPod value for all of these 
thresholds (p<0.0001).
Typical pump performance
The performance of a typical pump, selected as the pump that exhibited 
the median standard deviation in discrete pulse error, was investigated 
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Figure 2: Overall patch pump performance showing 
percentage error in single-pulse volume for the Cellnovo (A) 
and OmniPod (B) devices (n=6000 discrete pulses)
Table 1: Run protocol and description to evaluate system 
stability and patch pump reliability
Run period Pulse rate (hour-1) Description
Hours 0–1 0.0 Pre-run stability check
Hours 1–21 10–20 Test basal rate
Hours 21–22 0.0 Post-run stability check
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by plotting the single-pulse accuracy (Figure 5A and D), 10-pulse 
averaged accuracy (Figure 5B and E) and 20-pulse averaged accuracy 
(Figure 5C and F) of the device over the entire 20-hour test basal rate 
period. The Cellnovo pump exhibited markedly less variability in pulse 
accuracy (Figure 5A–C) than the OmniPod pump (Figure 5D–F). When 
dosing accuracy was averaged over a 2-hour time period the OmniPod 
profile still exhibited a highly variable dosing profile (Figure 5F). 
Industry-established low accuracy
Pump flow accuracy over the last 100 deliveries in the 20-hour test 
basal period was compared for a typical Cellnovo and OmniPod pump 
as outlined in EN 60601-2-24:2012. Maximum positive and negative 
percentage deviations across a 2, 5, 11, 19 and 31 pulse window were 
calculated (Figure 6). For both pumps the stabilisation period prior to the 
last 100 delivery assessment was 10 hours.
Discussion
Patch insulin infusion pumps are a relatively recent innovation aiming to 
increase CSII compliance for insulin-dependent diabetes patients. Whilst 
offering advantages in the form of discreteness, ease of use and overall 
patient satisfaction, a recent study found the dosing accuracy of a patch 
pump to be unfavourable compared to the traditional durable pumps;7 
it was significantly less accurate in terms of both single and averaged-
pulse measurements. 
The current technical evaluation has demonstrated that the Cellnovo 
device displayed significantly better single-pulse accuracy than 
the OmniPod pump when assessed over predetermined accuracy 
thresholds (±5–30%), and was significantly more accurate when 
assessed over longer, more clinically relevant observation doses 
(0.5–2 units).
The markedly different performance may be explained by the differing 
pumping mechanisms integral to these devices. Any shortcomings found 
in the delivery performance of the OmniPod system can be attributed 
to the disposable nature of the device. The results reflect those of Borot 
Table 2: Single and averaged-pulse accuracy of the two 
patch pump devices. Data shows the mean percentage 
of pulses delivered outside of single and averaged-pulse 
accuracy thresholds (±5-30%)
Dosing Accuracy over 20 hours
% outside accuracy threshold (6000 pulses)
Cellnovo OmniPod®
Single Dose (±)
5% 79.6 86.2
10% 55.6 71.6
15% 35.0 57.4
20% 19.9 45.5
25% 9.7 35.2
30% 4.3 25.4
0.5 Unit averaging window (±)
5% 51.5 76.9
10% 21.8 55.4
15% 7.3 37.6
20% 1.9 22.1
25% 0.7 13.1
30% 0.5 7.8
1 Unit averaging window (±)
5% 42.2 71.9
10% 10.9 48.5
15% 1.5 31.8
20% 0.2 17.6
25% 0.0 9.1
30% 0.0 5.3
2 Unit averaging window (±)
5% 37.9 66.3
10% 7.2 41.0
15% 0.4 25.9
20% 0.0 14.1
25% 0.0 7.7
30% 0.0 3.9
±5% ±10% ±15% ±20% ±25% ±30%
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Figure 3: The mean percentage of single pulses outside of 
the ±5, 10, 15, 20, 25 and 30% accuracy thresholds for the 
OmniPod and Cellnovo patch pumps over the 20-hour basal 
rate period
Figure 4: The mean percentage of pulses outside of the 
±15% accuracy threshold averaged over observation 
windows of 0.5, 1.0 and 2.0 units for the OmniPod and 
Cellnovo patch pumps over the 20-hour basal rate period
The percentage of delivered pulses outside of the accuracy thresholds was significantly 
lower for the Cellnovo pump at all thresholds (p<0.0001, n=30 runs ± standard deviation).
Dose-dose refers to single, non-averaged pulses. The percentage of delivered pulses 
outside of the accuracy threshold was significantly lower for the Cellnovo pump for all 
observation windows (p<0.0001, n=30 runs ± standard deviation). U=unit
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et al.,11, who used a similar method to Jahn et al.,7 excepting that they 
used the same method to test both types of pumps and as with the 
current study, placed the pumps outside the microbalance. Results 
demonstrated that in vitro, the patch pump studied was more accurate 
than the comparators, including the Omnipod.
Limitations
There have been discussions in the literature on the optimal manner 
in which insulin pump delivery should be measured for precision and 
accuracy.7,11,12,13 Jahn et al.7 discuss a methodology that compares a 
reduced number of durable systems (n=6) in comparison to the patch 
pump (n=15) and this could be seen as an inconsistency, leading to 
greater variability being witnessed in the larger sample number. 
However, in normal use, a patient would be wearing a single durable 
pump for four years and would change their patch pump every three 
days; this increases the need to understand the actions of disposable 
pumps both throughout their life and understanding the pump to 
pump (or pod to pod variability). It is believed that this information 
would have led to the increased n in the patch pump arm of the 
study, and also made fairer by the use of multiple durable pumps. 
The Cellnovo system in this test consists of a durable element and a 
3-day disposable element; it was however, tested by the same means 
as the disposable system. 
The experimental design of the current evaluation mirrored that of Jahn 
et al.7 with slight modifications, notably the infusion setup. This was 
for two reasons: first, while this study did not seek to compare testing 
methodologies, the authors took into account the comments made 
by Zisser12 about dose-to-dose delivery accuracy. Zisser12 suggested 
that in Jahn et al.’s. study,7 the positioning of the Omnipod within the 
microbalance may have been the reason for the measured oscillatory data 
seen in the Omnipod data. In this study this was taken into consideration 
and both patch pumps were positioned outside of the microbalance 
and connected via a tube to ensure a consistent and fair test; second, 
in the Jahn et al. study, durable pumps were attached to infusion lines 
Cellnovo
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Figure 5: 20-hour basal proiles of a typical Cellnovo (A-C) and OmniPod (D-F) patch pump showing single-pulse accuracy
(A,D), 10-pulse averaged accuracy (B,E) and 20-pulse averaged accuracy (C,F). For all figures the dotted horizontal lines indicate the ±5% accuracy range.
Figure 6: Trumpet curves for a typical Cellnovo and 
OmniPod patch pump device
Cellnovo (A) and OmniPod (B) patch pump device showing the maximum positive and 
maximum negative flow rate error (black solid lines) and the average flow rate error 
(black dotted line) for 2, 5, 11, 19 and 31 pulses.
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whereas the OmniPod pump was attached to the collecting vial directly 
by the device cannula. This was done to mirror the clinical situation, 
as durable pumps require infusion lines whereas patch pumps do not. 
However, this comes at the expense of introducing experimental design 
difference between the groups. Furthermore, we found that the short 
length of the cannula (6.5 mm for OmniPod, 5.0 mm for Cellnovo system) 
made it difficult to connect directly to the collecting vial whilst achieving 
a steady system setup. In this study both pumps were connected to the 
collecting vial by an infusion line ensuring both pumps were compared 
using identical experimental setups. Although this is a potential limitation 
of the study, as in practice patch pumps are free from infusion lines, it 
ensured a consistent and fair comparison between the pumps. 
As mentioned previously there are alternative methods for measuring 
pulsed dose accuracy.13 These methods are not easily employable for 
the measurement of large numbers of systems and care must be taken 
when measuring spheres with such small radii due to evaporation rates 
in varying environmental humilities. 
Conclusions
Whilst a previous study showed that a patch pump performed poorly 
when compared to a number of durable pumps, this study showed that 
not all patch pumps are the same. The pumping mechanisms employed 
in these pumps play a significant role in the accuracy and precision of 
such devices, which in turn may impact on clinical outcome. q
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